Summarized by Masters of Longevity from Longevity Technology.
Analysis of why regenerative cell therapy platforms can pursue multiple indications in parallel, using a specific Muse cell example to illustrate platform advantages.
Key Takeaways
- Regenerative platforms dominate renewal-stage value with $18 billion across 324 assets compared with $8.8 billion across 213 drug-like assets.
- Dezawa Muse cells show higher homing and delivery, with about 15% of infused dose reaching target lesions versus under 1% for standard MSCs.
- MuseCell-linked studies report safety and functional signals in acute myocardial infarction, ischemic stroke, and epidermolysis bullosa while four other indications run concurrently.
